Gastric Adenocarcinoma
2 competing products in clinical development for Gastric Adenocarcinoma.
Pipeline by Phase
Phase 11
Phase 21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| ASP2138 + Pembrolizumab + Oxaliplatin + Leucovorin + Fluorouracil + Ramucirumab + Paclitaxel + Irinotecan + Capecitabine | Astellas Pharma | Phase 1 | Recruiting | 36 |